Boehringer Ingelheim has launched a new vaccine against BTV-8. While most of the 316 identified cases of bluetongue in GB have been
BTV-3, BTV-8 has been identified on 11 farms, seven of which were also infected with BTV-3. In response to this emerging threat, Boehringer has produced BTV PUR to help the protect against this second circulating serotype.
“These cases may be the tip of the iceberg and more cases could be going undiagnosed,” says the firm’s Sioned Timothy. “Vaccination remains the most effective tool for protecting stock against the clinical effects of infection and helping to reduce onward spread of the virus.” Immunity starts three weeks after completion of the primary vaccination course of two 1ml doses three to four weeks apart. The vaccine can be used during pregnancy and lactation.
www.boehringer-ingelheim.com/uk
